Financial Information

SEC Filings

Filing date	Form	Description	Filing Group	View
Feb 24, 2020	DRS	Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy	Registration Statements	0000912057-20-000087.pdf 0000912057-20-000087.rtf 0000912057-20-000087.xls View HTML
Jul 08, 2014	DRS	Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy	Registration Statements	0001144204-14-041967.pdf 0001144204-14-041967.rtf 0001144204-14-041967.xls View HTML
Nov 09, 2017	DRS	Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy	Registration Statements	0000912057-17-000353.pdf 0000912057-17-000353.rtf 0000912057-17-000353.xls View HTML
Dec 20, 2017	DRS/A	mendment to a previously filed DRS	Registration Statements	0000912057-17-000396.pdf 0000912057-17-000396.rtf 0000912057-17-000396.xls View HTML
Oct 07, 2014	DRS/A	mendment to a previously filed DRS	Registration Statements	0001144204-14-059878.pdf 0001144204-14-059878.rtf 0001144204-14-059878.xls View HTML
Sep 24, 2014	DRS/A	mendment to a previously filed DRS	Registration Statements	0001144204-14-057570.pdf 0001144204-14-057570.rtf 0001144204-14-057570.xls View HTML
Jun 25, 2020	EFFECT	EFFECT	Other	9999999995-20-001545.xls View HTML
Jul 09, 2021	EFFECT	EFFECT	Other	9999999995-21-002712.pdf 9999999995-21-002712.rtf 9999999995-21-002712.xls View HTML
Feb 13, 2024	EFFECT	EFFECT	Other	9999999995-24-000428.pdf 9999999995-24-000428.rtf 9999999995-24-000428.xls View HTML
Feb 08, 2018	F-1	Registration statement for certain foreign private issuers	Registration Statements	0001047469-18-000675.pdf 0001047469-18-000675.rtf 0001047469-18-000675.xls View HTML

Data provided by Kaleidoscope.

Technology

PolyPid’s PLEX targeted drug delivery platform enables localized, controlled, continuous release of medication over prolonged periods of time for better patient outcomes.

D-PLEX₁₀₀

Provides safe and effective local antibiotic protection against SSI (surgical Site Infection) at the needed tissues or organs by administration during surgical procedures.

D-PLEX₁₀₀₀

Comprised of antibiotic eluting ß tri-calcium phosphate (ßTCP) granules, designed for bone related infections applications.